Patents Examined by Lea S O'Brien
  • Antibodies specific to delta 1 chain of T cell receptor
    Patent number: 12084500
    Abstract: Disclosed herein are antibodies specific to a delta-1 chain of a ?? T cell receptor and methods of using such for modulating ?? T cell bioactivity. Such anti-Delta 1 antibodies may also be used to treat diseases associated with ?? T cell activation, such as solid tumors, or for detecting presence of ??1 T cells.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: September 10, 2024
    Assignees: New York University, PureTech LYT, Inc.
    Inventors: Shohei Koide, George Miller, Akiko Koide, Tatyana Panchenko, Takamitsu Hattori, Aleksandra Filipovic, Eric Elenko, Joseph Bolen
  • Anti-ULBP6 antibodies
    Patent number: 12060426
    Abstract: The present disclosure relates to a ULBP6 binding protein that inhibits the interaction between ULBP6 and NKG2D, and methods of treating cancer with said ULBP6 binding protein.
    Type: Grant
    Filed: April 28, 2023
    Date of Patent: August 13, 2024
    Assignee: 23andMe, Inc.
    Inventors: Joel Benjamin, Shashank Bharill, I-Ling Chen, Yu Chen, Wei-Jen Chung, Zahra Bahrami Dizicheh, Germaine Fuh, Patrick Koenig, Yujie Liu, Mauro Poggio, Shruti Yadav, Ping-Chiao Tsai, Claus Spitzfaden
  • Humanized anti-human CTLA4 monoclonal antibody, preparation method therefor and use thereof
    Patent number: 12037396
    Abstract: The present invention relates to a humanized anti-human CTLA4 monoclonal antibody. The present invention also relates to a preparation method and application of the humanized anti-human CTLA4 monoclonal antibody.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: July 16, 2024
    Assignee: Nanjing GenScript Biotech Co., Ltd.
    Inventors: Liusong Yin, Tielin Zhou, Zhuo Fang, Yanling Mi, Chunchen Wu